Question 1

What are the potential benefits of this new therapy compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from the CD19/CD22 bispecific CAR-T therapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or complications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any other treatment options I should consider alongside this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

Question 6

How long will I need to participate in the trial and what will my visits look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia clinical trial (NCT06081478). Contact the study team or your healthcare provider for specific answers.

What this study is about